To learn more about these conditions and how Praluent helps treat them, see the “What is Praluent used for?” section below. Praluent is given as an injection under your skin. Praluent contains the ...
TARRYTOWN, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced the U.S. Food & Drug Administration (FDA) has extended the approval of Praluent ® ...
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced they will lower the net price of Praluent ® (alirocumab) Injection in exchange for straightforward, more affordable patient ...
Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) of the U.S. Food and Drug Administration (FDA) recommended the ...
Regeneron's Praluent injection gets FDA approval to treat kids with genetic form of high cholesterol
Regeneron Pharmaceuticals (NASDAQ:REGN) has received approval from the U.S. Food & Drug Administration (FDA) for its Praluent (alirocumab) injection to treat children with genetic form of high ...
TARRYTOWN, N.Y. and PARIS, Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent ® (alirocumab) Injection met its ...
TARRYTOWN, Regeneron Pharmaceuticals, Inc. Sanofi today announced that the companies have completed enrollment in the global Phase 3 ODYSSEY OUTCOMES trial, which is prospectively evaluating the ...
- Primary results from ongoing 52 week ODYSSEY JAPAN trial presented at the Japanese Atherosclerosis Society (JAS) Annual Scientific Meeting - - Ninety-nine percent of patients treated with Praluent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback